The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)



Pfizer Europe MA EEIGEU/1/23/1752/001-006

Main Information

Trade NameAbrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)
Active SubstancesRespiratory syncytial virus, subgroup A, stabilized prefusion F protein 847A
Respiratory syncytial virus, subgroup B, stabilized prefusion F protein 847B
Dosage FormPowder and solvent for solution for injection
Licence HolderPfizer Europe MA EEIG
Licence NumberEU/1/23/1752/001-006

Group Information

ATC CodeJ07BX05 respiratory syncytial virus vaccines

Status

License statusAuthorised
Licence Issued23/08/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back